| Literature DB >> 30318966 |
Zihao Zhang1, Bin Shen2.
Abstract
Local infiltration analgesia has been widely used for pain relief in patients undergoing total knee arthroplasty. However, the effectiveness and major weakness of this technique have not been clarified; therefore, improvements in the technique have been limited. We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials and conducted a meta-analysis of randomized controlled trials comparing local infiltration analgesia with placebo infiltration in patients undergoing total knee arthroplasty. Fourteen trials involving 1305 knees were eligible. The results showed that local infiltration analgesia significantly reduced early perioperative pain and total narcotic consumption. However, postoperative functional outcomes were not significantly different between local infiltration analgesia and placebo. The pain-relieving effect of local infiltration analgesia was found to be strong but short in duration. In the future, modified delivery methods and formulas with longer durations of action and analgesia may provide a better environment for patients and therefore improve their function outcomes.Entities:
Keywords: Local infiltration analgesia; meta-analysis; narcotic consumption; perioperative pain; placebo; randomized controlled trial; total knee arthroplasty
Mesh:
Substances:
Year: 2018 PMID: 30318966 PMCID: PMC6300945 DOI: 10.1177/0300060518799616
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671
Figure 1.Flow chart of study inclusion process.
General demographic characteristics.
| Study | Pts | Knees | Sex | Mean age, y | BMI, kg/m2 | ASA | Diagnosis | Total follow-up | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | LIA | NS | M | F | I/II | III | ||||||
| Browne et al. | 60 | 60 | 30 | 30 | 21 | 39 | 67 | – | – | OA (57) | 1 d | |
| Nechleba et al. | 30 | 30 | 14 | 16 | 11 | 19 | 65 | – | – | OA (60) | 3 d | |
| Andersen et al. | 12 | 24 | 12 | 12 | 7 | 5 | 69 | 29 | 11 | 1 | – | 2 d |
| Krenzel et al. | 66 | 67 | 35 | 32 | 23 | 43 | 66.2 | – | – | OA (63),RA (3) | 1 d | |
| Reeves and Skinner | 61 | 61 | 31 | 30 | 25 | 36 | 69.5 | – | 48 | 12 | – | 3 d |
| Andersen et al. | 16 | 32 | 16 | 16 | 9 | 7 | 63 | 31 | 16 | 0 | – | 1 d |
| Essving et al. | 48 | 48 | 24 | 24 | 22 | 26 | 71 | – | 47 | 1 | OA (48) | 3 m |
| Gómez-Cardero and Rodríguez-Merchán | 50 | 50 | 25 | 25 | 19 | 31 | 71.3 | – | – | OA (48) | 1 m | |
| Kazak et al. | 60 | 60 | 40 | 20 | 11 | 49 | 69.7 | – | 45 | 15 | – | 2 d |
| Fajardo et al. | 30 | 60 | 30 | 30 | 7 | 23 | 63.5 | – | – | OA (30) | 3 d | |
| Joo et al. | 286 | 572 | 286 | 286 | 14 | 272 | 79.1 | 27.4 | – | OA (286) | 14 d | |
| Ikeuchi et al. | 40 | 40 | 20 | 20 | 12 | 28 | 75.5 | – | – | OA (40) | 3 m | |
| Goyal et al. | 150 | 150 | 75 | 75 | 65 | 85 | 63.9 | 30 | – | OA (150) | 3 d | |
| Williams et al. | 51 | 51 | 26 | 25 | 21 | 30 | 66.5 | 29.4 | 16 | 35 | OA (51) | 1 y |
Pts, patients; LIA, local infiltration analgesia; NS, normal saline; M, male; F, female; BMI, body mass index; ASA, American Society of Anesthesiologists physical status; OA, osteoarthritis; RA, rheumatoid arthritis.
Anesthetic and surgical information.
| Study | Surgical approach | Infiltration information | Main analgesia schemes | Length of surgery, minutes | |||
|---|---|---|---|---|---|---|---|
| Main drug | Supplements | Timing | LIA | NS | |||
| Browne et al. | MP,MV | Bupivacaine | Epinephrine | Intra-op | PCA morphine,IM narcotics,Oral narcotics | 106 | 100 |
| Nechleba et al. | MP | Bupivacaine | None | Post-op | PCA morphine,Oral narcotics | – | – |
| Andersen et al. | MP | Ropivacaine | Epinephrine | Post-op | PCA morphine,Oral narcotics | 109 | 109 |
| Krenzel et al. | MP | Ropivacaine | None | Intra to post-op | PCA morphine,FNB,Oral narcotics | – | – |
| Reeves and Skinner | MP | Ropivacaine | None | Post-op | SQ morphine,FNB,Oral narcotics | 114 | 103 |
| Andersen et al. | MP | Ropivacaine | None | Intra to post-op | PCA morphine,Oral narcotics | 100 | 100 |
| Essving et al. | MP | Ropivacaine | Epinephrine,Ketorolac | Intra to post-op | PCA morphine,Oral narcotics | 93 | 87 |
| Gómez-Cardero and Rodríguez-Merchán | MV | Ropivacaine | None | Post-op | SQ and IV pethidine,Oral narcotics | – | – |
| Kazak et al. | MP | Bupivacaine,Levobupivacaine | Epinephrine | Intra and post-op | PCA tramadol,Oral narcotics | 102 | 85 |
| Fajardo et al. | MP,SV | Bupivacaine | Epinephrine,Ketorolac,Morphine | Intra-op | Oral narcotics | – | – |
| Joo et al. | MP | Bupivacaine | Epinephrine, Methylprednisolone,Morphine | Intra-op | PCA morphine,Oral narcotics,Fentanyl patch | 73 | 73 |
| Ikeuchi et al. | MP | Ropivacaine | Epinephrine,Dexamethasone, Isepamicin | Intra to post-op | PCA fentanyl,Oral narcotics | 115 | 119 |
| Goyal et al. | MP | Bupivacaine | None | Post-op | Oral narcotics | – | – |
| Williams et al. | MP | Bupivacaine | None | Post-op | PCA morphine,Oral narcotics | – | – |
MP, medial parapatellar approach; MV, midvastus approach; SV, subvastus approach; PCA, patient-controlled analgesia; IM, intramuscular; FNB, femoral nerve block; SQ, subcutaneous; IV, intravenous; LIA, local infiltration analgesia; NS, normal saline infiltration.
Quality assessment using the modified Jadad score.
| Study | Randomization | Blinding | Dropouts | Inclusion/exclusion criteria | Adverse effects assessment | Statistical analysis | Modified Jadad score | ||
|---|---|---|---|---|---|---|---|---|---|
| Described | Appropriate | Described | Appropriate | ||||||
| Browne et al. | Yes | Unclear | Yes | Unclear | Not described | Described | Described | Described | 5 |
| Nechleba et al. | Yes | Unclear | Yes | Unclear | Not described | Not described | Described | Described | 4 |
| Andersen et al. | Yes | Yes | Yes | Yes | Not described | Described | Not described | Described | 6 |
| Krenzel et al. | Yes | Unclear | Yes | Unclear | Not described | Described | Not described | Described | 4 |
| Reeves and Skinner | Yes | Unclear | Yes | Yes | Described | Not described | Described | Described | 6 |
| Andersen et al. | Yes | Unclear | Yes | Yes | Not described | Described | Not described | Described | 5 |
| Essving et al. | Yes | Yes | Yes | Yes | Described | Described | Described | Described | 8 |
| Gómez-Cardero and Rodríguez-Merchán | Yes | Unclear | Yes | Unclear | Not described | Described | Not described | Described | 4 |
| Kazak et al. | Yes | Unclear | Yes | Yes | Not described | Described | Described | Described | 6 |
| Fajardo et al. | Yes | Unclear | Yes | Unclear | Not described | Described | Not described | Described | 4 |
| Joo et al. | Yes | Yes | Yes | Yes | Described | Described | Described | Described | 8 |
| Ikeuchi et al. | Yes | Unclear | Yes | Yes | Not described | Described | Described | Described | 6 |
| Goyal et al. | Yes | Yes | Yes | Yes | Described | Described | Described | Described | 8 |
| Williams et al. | Yes | Yes | Yes | Yes | Described | Described | Described | Described | 8 |
Meta-analysis results of outcome indicators.
| Outcome indicators | Studies (n) | Knees | Mean difference/odds ratio | |||
|---|---|---|---|---|---|---|
| Value (95% CI) | Heterogeneity | Model | ||||
| Visual analogue scale score | 5 | 358 | 0.003 | −0.66 (−1.08 to −0.23) | 0.37 (6%) | Fixed |
| Narcotic dose equivalent | 8 | 507 | 0.03 | −1.01 (−1.90 to −0.11) | <0.0001 (79%) | Random |
| Adverse effects | 4 | 301 | 0.84 | 0.93 (0.47 to 1.85) | 0.67 (0%) | Fixed |
| Range of motion | 4 | 196 | 0.20 | 9.33 (−5.02 to 23.69) | <0.00001 (93%) | Random |
| Ambulation distance | 2 | 97 | 0.13 | 13.40 (−3.90 to 30.69) | 0.48 (0%) | Fixed |
| Straight-leg raise | 2 | 107 | 0.10 | 2.02 (0.88 to 4.62) | 0.53 (0%) | Fixed |
| Oxford score | 2 | 99 | 0.37 | 1.17 (−1.38 to 3.71) | 0.86 (0%) | Fixed |
| Length of hospital stay | 4 | 310 | 0.50 | −0.31 (−1.20 to 0.58) | 0.0002 (85%) | Random |
CI, confidence interval.